Literature DB >> 6761644

Experimental bovine group-B streptococcal mastitis induced by strains of human and bovine origin.

N E Jensen.   

Abstract

Intramammary infections with Group-B streptococci of human and bovine origin were produced experimentally in cows. The initial cytological response was more rapid to the human than to the bovine strain (Table I), while at later stages the pathological changes induced by the two infections were much the same (Fig. 1). The initial clinical reaction was more acute to the "human" than to the "bovine" infections and the average daily loss of milk was greater in cases of "human" infection than in cases of "bovine" infection (Table II). In contrast to the "bovine" infections the "human" infections showed a pronounced tendency to spontaneous clearance. The rate of excretion of Group-B streptococci with the milk was lower for the "human" than for the "bovine" infections (Table III). The special mode of reaction of the bovine udder against infections with Group-B streptococci of human origin may, in part, explain why such infections have a lower tendency to spread within a herd than infections with bovine strains of B-streptococci.

Entities:  

Mesh:

Year:  1982        PMID: 6761644

Source DB:  PubMed          Journal:  Nord Vet Med        ISSN: 0029-1579


  13 in total

1.  Epidemiological aspects of group B streptococci of bovine and human origin.

Authors:  N E Jensen; F M Aarestrup
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

2.  Distribution of serotypes and antimicrobial resistance genes among Streptococcus agalactiae isolates from bovine and human hosts.

Authors:  Belgin Dogan; Y H Schukken; C Santisteban; Kathryn J Boor
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Molecular subtyping and characterization of bovine and human Streptococcus agalactiae isolates.

Authors:  Sharinne Sukhnanand; Belgin Dogan; Maranatha O Ayodele; Ruth N Zadoks; Mary Patricia J Craver; Nellie B Dumas; Ynte H Schukken; Kathryn J Boor; Martin Wiedmann
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  The kinetics of inflammation and phagocytosis during bovine mastitis induced by Streptococcus agalactiae bearing the protein X.

Authors:  P Rainard; Y Lautrou; P Sarradin; A Coulibaly; B Poutrel
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

5.  Efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs.

Authors:  D W Scott; W H Miller; S M Cayatte; M S Bagladi
Journal:  Can Vet J       Date:  1994-10       Impact factor: 1.008

Review 6.  Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans.

Authors:  Ruth N Zadoks; John R Middleton; Scott McDougall; Jorgen Katholm; Ynte H Schukken
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-04       Impact factor: 2.673

7.  Changing trends in mastitis.

Authors:  Rn Zadoks; Jl Fitzpatrick
Journal:  Ir Vet J       Date:  2009-04-01       Impact factor: 2.146

8.  Streptococcus agalactiae Serotype IV in Humans and Cattle, Northern Europe1.

Authors:  Ulrike Lyhs; Laura Kulkas; Jørgen Katholm; Karin Persson Waller; Kerttu Saha; Richard J Tomusk; Ruth N Zadoks
Journal:  Emerg Infect Dis       Date:  2016-12       Impact factor: 6.883

9.  Streptococcus agalactiae is not always an obligate intramammary pathogen: Molecular epidemiology of GBS from milk, feces and environment in Colombian dairy herds.

Authors:  Claudia Cobo-Ángel; Ana S Jaramillo-Jaramillo; Laura M Lasso-Rojas; Sandra B Aguilar-Marin; Javier Sanchez; Juan C Rodriguez-Lecompte; Alejandro Ceballos-Márquez; Ruth N Zadoks
Journal:  PLoS One       Date:  2018-12-10       Impact factor: 3.240

10.  Galleria mellonella as an infection model for the multi-host pathogen Streptococcus agalactiae reflects hypervirulence of strains associated with human invasive disease.

Authors:  Anne Six; Sakranmanee Krajangwong; Margaret Crumlish; Ruth N Zadoks; Daniel Walker
Journal:  Virulence       Date:  2019-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.